Emerging clinical issues related to management of multiorgan comorbidities and polypharmacy

Current Opinion in HIV and AIDS

Volumn 9, Issue 4, 2014, Pages 371-378

  Vigouroux, Corinne ^a,b,c   Bastard, Jean Philippe ^a,b,c   Capeau, Jacqueline ^a,b,c,d  

^a SORBONNE UNIVERSITÉ   (France)

^b HÔPITAL TENON   (France)

^c ICAN   (France)

^d ANRS   (France)

Author keywords

aging biomarkers; anti inflammatory immune modulatory drugs; benefit risk ratio; comorbidities; HIV management

Indexed keywords

ACETYLSALICYLIC ACID; ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE ANTIBODY; HERBACEOUS AGENT; HISTONE DEACETYLASE INHIBITOR; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOMODULATING AGENT; INTEGRASE INHIBITOR; INTERLEUKIN 6 ANTIBODY; LEFLUNOMIDE; MESSENGER RNA; METHOTREXATE; MITOCHONDRIAL DNA; NON PRESCRIPTION DRUG; PREBIOTIC AGENT; PROBIOTIC AGENT; RAPAMYCIN; RAPAMYCIN DERIVATIVE; RESVERATROL; RNA DIRECTED DNA POLYMERASE INHIBITOR; SEVELAMER; UNINDEXED DRUG; VACCINE; VALGANCICLOVIR; VITAMIN D;

ADULT; AGED; AGING; CARDIOVASCULAR DISEASE; CD4 CD8 RATIO; CD4 LYMPHOCYTE COUNT; CLINICAL ASSESSMENT; COHORT ANALYSIS; COMORBIDITY; CYTOMEGALOVIRUS INFECTION; DISABILITY; DNA METHYLATION; FRAIL ELDERLY; HEALTH CARE PERSONNEL; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; INTESTINE FLORA; LIFE EXPECTANCY; LIFESTYLE MODIFICATION; LIPODYSTROPHY; NONHUMAN; PATIENT CARE; PATIENT COMPLIANCE; POLYPHARMACY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SENESCENCE; VETERAN; VIREMIA; COMPLICATION; HIV INFECTIONS; ORGANIZATION AND MANAGEMENT; PROCEDURES;

AGING; COMORBIDITY; HIV INFECTIONS; HUMANS; PATIENT CARE MANAGEMENT; POLYPHARMACY;

EID: 84902299892     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000068     Document Type: Review

References (72)

1. Greene M, Justice AC, Lampiris HW, Valcour V. Management of human immunodeficiency virus infection in advanced age. JAMA 2013; 309:1397-1405.
2. Pathai S, Bajillan H, Landay AL, High KP. Is HIV a model of accelerated or accentuated aging? J Gerontol A Biol Sci Med Sci 2013. doi: 10. 1093 Epub ahead of print
3. Wada N, Jacobson LP, Cohen M, et al. Cause-specific mortality among HIVinfected individuals, by CD4 cell count at HAART initiation, compared with HIV-uninfected individuals. AIDS 2014; 28:257-265.
4. Justice AC, Braithwaite RS. Lessons learned from the first wave of aging with HIV. AIDS 2012; 26 (Suppl 1):S11-S18.
5. Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet 2013; 382:1525-1533.
6. Valdes AM, Glass D, Spector TD. Omics technologies and the study of human ageing. Nat Rev Genet 2013; 14:601-607.
7. Kirkwood TB. Understanding the odd science of aging. Cell 2005; 120:437-447.
8. Caron M, Auclair M, Donadille B, et al. Human lipodystrophies linked to mutations in A-type lamins and to HIV protease inhibitor therapy are both associated with prelamin A accumulation, oxidative stress and premature cellular senescence. Cell Death Differ 2007; 14:1759-1767.
9. Ragnauth CD, Warren DT, Liu Y, et al. Prelamin A acts to accelerate smooth muscle cell senescence and is a novel biomarker of human vascular aging. Circulation 2010; 121:2200-2210.
10. Freund A, Orjalo AV, Desprez PY, Campisi J. Inflammatory networks during cellular senescence: causes and consequences. Trends Mol Med 2010; 16:238-246.
11. Lopez-Otin C, Blasco MA, Partridge L, et al. The hallmarks of aging. Cell 2013; 153:1194-1217.
12. High KP, Brennan-Ing M, Clifford DB, et al. HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr 2012; 60 (Suppl 1):S1-S18.
13. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
14. Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011; 203: 780-790.
15. Project GfHaAC. Summary report from the Human Immunodeficiency Virus and Aging Consensus Project: treatment strategies for clinicians managing older individuals with the human immunodeficiency virus. J Am Geriatr Soc 2012; 60:974-979.
16. Serrano-Villar S, Moreno S, Fuentes-Ferrer M, et al. The CD4:CD8 ratio is associated with markers of age-associated disease in virally suppressed HIVinfected patients with immunological recovery. HIV Med 2014; 15:40-49.
17. Lang S, Mary-Krause M, Simon A, et al. HIV replication and immune status are independent predictors of the risk of myocardial infarction in HIV-infected individuals. Clin Infect Dis 2012; 55:600-607.
18. Guiguet M, Boue F, Cadranel J, et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDHANRS CO4): a prospective cohort study. Lancet Oncol 2009; 10:1152-1159.
19. Shah K, Hilton TN, Myers L, et al. A new frailty syndrome: central obesity and frailty in older adults with the human immunodeficiency virus. J Am Geriatr Soc 2012; 60:545-549.
20. Mynarcik DC, McNurlan MA, Steigbigel RT, et al. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr 2000; 25:312-321.
21. Vigouroux C, Maachi M, Nguyen TH, et al. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS 2003; 17:1503-1511.
22. Boufassa F, Goujard C, Viard JP, et al. Immune deficiency could be an early risk factor for altered insulin sensitivity in antiretroviral-naive HIV-1-infected patients: the ANRS COPANA cohort. Antivir Ther 2012; 17:91-100.
23. Althoff KN, Jacobson LP, Cranston RD, et al. Age, comorbidities, and AIDS predict a frailty phenotype in men who have sex with men. J Gerontol A Biol Sci Med Sci 2014; 69:189-198.
24. Pathai S, Lawn SD, Weiss HA, et al. Increased ocular lens density in HIVinfected individuals with low nadir CD4 counts in South Africa: evidence of accelerated aging. J Acquir Immune Defic Syndr 2013; 63:307-314.
25. Pathai S, Lawn SD, Shiels PG, et al. Corneal endothelial cells provide evidence of accelerated cellular senescence associated with HIV infection: a case-control study. PLoS One 2013; 8:e57422.
26. Payne BA, Wilson IJ, Hateley CA, et al. Mitochondrial aging is accelerated by antiretroviral therapy through the clonal expansion of mtDNA mutations. Nat Genet 2011; 43:806-810.
27. Payne BA, Hollingsworth KG, Baxter J, et al. In vivo mitochondrial function in hiv-infected persons treated with contemporary anti-retroviral therapy: a magnetic resonance spectroscopy study. PLoS One 2014; 9:e84678.
28. Jacob KD, Noren Hooten N, Trzeciak AR, Evans MK. Markers of oxidant stress that are clinically relevant in aging and age-related disease. Mech Ageing Dev 2013; 134:139-157.
29. Kirk JB, Goetz MB. Human immunodeficiency virus in an aging population, a complication of success. J Am Geriatr Soc 2009; 57:2129-2138.
30. Tenorio AR, Zheng Y, Bosch RJ, et al. Soluble markers of inflammation & coagulation, but not T-cell activation, predict non-AIDS-defining events during suppressive antiretroviral therapy (ART). Conference on Retroviruses and Opportunistic Infections (CROI) 2013, Atlanta USA, abstract 790.
31. Vujkovic-Cvijin I, Dunham RM, Iwai S, et al. Dysbiosis of the gut microbiota is associated with hiv disease progression and tryptophan catabolism. Sci Transl Med 2013; 5:193ra191.
32. Pedersen KK, Pedersen M, Troseid M, et al. Microbial translocation in HIV infection is associated with dyslipidemia, insulin resistance, and risk of myocardial infarction. J Acquir Immune Defic Syndr 2013; 64:425-433.
33. Leeansyah E, Cameron PU, Solomon A, et al. Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging. J Infect Dis 2013; 207:1157-1165.
34. Zanet DL, Thorne A, Singer J, et al. Association between short leukocyte telomere length and HIV infection in a cohort study; no evidence of a relationship with antiretroviral therapy. Clin Infect Dis 2014; 58:1322-1332.
35. Liu Y, Sanoff HK, Cho H, et al. Expression of p16(INK4a) in peripheral blood T-cells is a biomarker of human aging. Aging Cell 2009; 8:439-448.
36. Nelson JA, Krishnamurthy J, Menezes P, et al. Expression of p16(INK4a) as a biomarker of T-cell aging in HIV-infected patients prior to and during antiretroviral therapy. Aging Cell 2012; 11:916-918.
37. Coffinier C, Hudon SE, Lee R, et al. A potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells. J Biol Chem 2008; 283:9797-9804.
38. Lefevre C, Auclair M, Boccara F, et al. Premature senescence of vascular cells is induced by HIV protease inhibitors: implication of prelamin A and reversion by statin. Arterioscler Thromb Vasc Biol 2010; 30:2611-2620.
39. D'Agostino RB Sr. Cardiovascular risk estimation in 2012: lessons learned and applicability to the HIV population. J Infect Dis 2012; 205 (Suppl 3): S362-S367.
40. Leslie WD, Brennan SL, Lix LM, et al. Direct comparison of eight national FRAX(R) tools for fracture prediction and treatment qualification in Canadian women. Arch Osteoporos 2013; 8:145.
41. Battalora LA, Buchacz K, Armon C, et al. New fracture risk and FRAX 10-year probability of fracture in HIV-infected adults. Conference on Retroviruses and Opportunistic Infections (CROI) 2014, Boston USA, abstract 778.
42. Peters BS, Perry M, Wierzbicki AS, et al. A cross-sectional randomised study of fracture risk in people with HIV infection in the probono 1 study. PLoS One 2013; 8:e78048.
43. Justice AC, Freiberg MS, Tracy R, et al. Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV? Clin Infect Dis 2012; 54:984-994.
44. Womack JA, Goulet JL, Gibert C, et al. Physiologic frailty and fragility fracture in HIV-infected male veterans. Clin Infect Dis 2013; 56:1498-1504.
45. Marquine MJ, Umlauf A, Rooney AS, et al. The veterans aging cohort study index is associated with concurrent risk for neurocognitive impairment. J Acquir Immune Defic Syndr 2014; 65:190-197.
46. Oursler KK, Tate JP, Gill TM, et al. Association of the veterans aging cohort study index with exercise capacity in HIV-infected adults. AIDS Res Hum Retroviruses 2013; 29:1218-1223.
47. Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 2011; 53:1120-1126.
48. Agarwal N, Iyer D, Patel SG, et al. HIV-1 Vpr induces adipose dysfunction in vivo through reciprocal effects on PPAR/GR co-regulation. Sci Transl Med 2013; 5:213ra164.
49. Chowdhury A, Silvestri G. Host-pathogen interaction in HIV infection. Curr Opin Immunol 2013; 25:463-469.
50. Edelman EJ, Gordon KS, Glover J, et al. The next therapeutic challenge in HIV: polypharmacy. Drugs Aging 2013; 30:613-628.
51. Hasse B, Ledergerber B, Furrer H, et al. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis 2011; 53:1130-1139.
52. Gleason LJ, Luque AE, Shah K. Polypharmacy in the HIV-infected older adult population. Clin Interv Aging 2013; 8:749-763.
53. van Breukelen-van der Stoep DF, Klop B, van Zeben D, et al. Cardiovascular risk in rheumatoid arthritis: how to lower the risk? Atherosclerosis 2013; 231:163-172.
54. Deeks SG, Tracy R, Douek DC. Systemic effects of inflammation on health during chronic HIV infection. Immunity 2013; 39:633-645.
55. Rajasuriar R, Khoury G, Kamarulzaman A, et al. Persistent immune activation in chronic HIV infection: do any interventions work? AIDS 2013; 27:1199-1208.
56. Rasmussen LD, Kronborg G, Larsen CS, et al. Statin therapy and mortality in HIV-infected individuals; a Danish nationwide population-based cohort study. PLoS One 2013; 8:e52828.
57. Overton ET, Kitch D, Benson CA, et al. Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death. Clin Infect Dis 2013; 56:1471-1479.
58. Moore RD, Bartlett JG, Gallant JE. Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients. PLoS One 2011; 6:e21843.
59. Piconi S, Parisotto S, Rizzardini G, et al. Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. Blood 2011; 118:3263-3272.
60. Paton NI, Goodall RL, Dunn DT, et al. Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial. JAMA 2012; 308:353-361.
61. Burkholder GA, Tamhane AR, Salinas JL, et al. Underutilization of aspirin for primary prevention of cardiovascular disease among HIV-infected patients. Clin Infect Dis 2012; 55:1550-1557.
62. Barnett H, Burrill P, Iheanacho I. Don't use aspirin for primary prevention of cardiovascular disease. BMJ 2010; 340:c1805.
63. Lake J, McComsey G, Hulgan T, et al. Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial. HIV Med 2014; doi: 10. 1111. [Epub ahead of print]
64. Massanella M, Negredo E, Puig J, et al. Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery. AIDS 2012; 26:2285-2293.
65. Hunt PW, Shulman NS, Hayes TL, et al. The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4T-cell recovery: a randomized trial. Blood 2013; 121:4635-4646.
66. Yonkers NL, Sieg S, Rodriguez B, Anthony DD. Reduced naive CD4 T cell numbers and impaired induction of CD27 in response to T cell receptor stimulation reflect a state of immune activation in chronic hepatitis C virus infection. J Infect Dis 2011; 203:635-645.
67. Klenerman P, Thimme R. T cell responses in hepatitis C: the good, the bad and the unconventional. Gut 2012; 61:1226-1234.
68. Joshi D, O'Grady J, Dieterich D, et al. Increasing burden of liver disease in patients with HIV infection. Lancet 2011; 377:1198-1209.
69. Wendt A, Adhoute X, Castellani P, et al. Chronic hepatitis C: future treatment. Clin Pharmacol 2014; 6:1-17.
70. Marchal J, Pifferi F, Aujard F. Resveratrol in mammals: effects on aging biomarkers, age-related diseases, and life span. Ann N Y Acad Sci 2013; 1290:67-73.
71. Broskey NT, Greggio C, Boss A, et al. Skeletal muscle mitochondria in the elderly: effects of physical fitness and exercise training. J Clin Endocrinol Metab 2014; jc20133983. [Epub ahead of print]
72. Greysen SR, Horwitz LI, Covinsky KE, et al. Does social isolation predict hospitalization and mortality among HIV and uninfected older veterans? J Am Geriatr Soc 2013; 61:1456-1463.